MyoKardia Inc. (NASDAQ:MYOK) raised $183.8 million late Tuesday through the sale of 3.8 million shares at $49 in a follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse and Wells Fargo. The price is a 1% premium to the company's close of $48.35 on Monday, when MyoKardia proposed the offering after market hours.
This quarter, the cardiovascular company expects to dose the first patient in the Phase III Explorer-HCM trial evaluating its lead candidate mavacamten to treat symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Data are due in 2H20.
Mavacamten is a small molecular allosteric modulator of cardiac myosin.
MyoKardia slipped $1.80 to $48.55 in afternoon trading Wednesday.